1. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group Study AREN0532
- Author
-
Robert C. Shamberger, Yeonil Kim, Elizabeth J. Perlman, James R. Anderson, Paul E. Grundy, Geetika Khanna, Peter F. Ehrlich, Zelig Tochner, Thomas E. Hamilton, John A. Kalapurakal, James I. Geller, Fredric A. Hoffer, Kenneth W. Gow, Elizabeth Mullen, Yueh Yun Chi, Janice S. Withycombe, Jeffrey S. Dome, Conrad V. Fernandez, and Arnold dela Cruz Paulino
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,Time Factors ,medicine.medical_treatment ,Loss of Heterozygosity ,Nephrectomy ,0302 clinical medicine ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Prospective Studies ,Stage (cooking) ,Child ,Prospective cohort study ,ORIGINAL REPORTS ,Kidney Neoplasms ,Progression-Free Survival ,Phenotype ,Chromosomes, Human, Pair 1 ,Vincristine ,Child, Preschool ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Dactinomycin ,Female ,Erratum ,medicine.drug ,medicine.medical_specialty ,Adolescent ,Radiation Dosage ,Wilms Tumor ,03 medical and health sciences ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,Progression-free survival ,Neoplasm Staging ,business.industry ,Infant ,Wilms' tumor ,Chemoradiotherapy, Adjuvant ,medicine.disease ,Radiation therapy ,Regimen ,030104 developmental biology ,Doxorubicin ,Lymph Nodes ,business ,Chromosomes, Human, Pair 16 ,Chemoradiotherapy - Abstract
Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology Wilms tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy. Further risk stratification is required to improve outcomes and reduce late effects. We evaluated clinical and biologic variables for patients with stage III FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p and 16q treated in the Children’s Oncology Group protocol AREN0532. Methods From October 2006 to August 2013, 588 prospectively treated, centrally reviewed patients with stage III FHWT were treated with Regimen DD4A and radiation therapy. Tumor LOH at 1p and 16q was determined by microsatellite analysis. Ineligible patients (n = 5) and those with combined LOH 1p/16q (n = 40) were excluded. Results A total of 535 patients with stage III disease were studied. Median follow-up was 5.2 years (range, 0.2 to 9.5). Four-year event-free survival (EFS) and overall survival estimates were 88% (95% CI, 85% to 91%) and 97% (95% CI, 95% to 99%), respectively. A total of 58 of 66 relapses occurred in the first 2 years, predominantly pulmonary (n = 36). Eighteen patients died, 14 secondary to disease. A better EFS was associated with negative lymph node status ( P < .01) and absence of LOH 1p or 16q ( P < .01), but not with gross residual disease or peritoneal implants. In contrast, the 4-year EFS was only 74% in patients with combined positive lymph node status and LOH 1p or 16q. A total of 123 patients (23%) had delayed nephrectomy. Submitted delayed nephrectomy histology showed anaplasia (n = 8; excluded from survival analysis); low risk/completely necrotic (n = 7; zero relapses), intermediate risk (n = 63; six relapses), and high-risk/blastemal type (n=7; five relapses). Conclusion Most patients with stage III FHWT had good EFS/overall survival with DD4A and radiation therapy. Combined lymph node and LOH status was highly predictive of EFS and should be considered as a potential prognostic marker for future trials.
- Published
- 2017